The Everolimus Eluting Cobalt Chromium Coronary Stent System is an advanced drug-eluting stent (DES) engineered to treat coronary artery disease (CAD) with superior precision and long-term efficacy. Designed with a cobalt-chromium alloy platform, it combines high radial strength with ultra-thin struts to ensure optimal vessel support, flexibility, and excellent deliverability in complex lesions.

Drug Coating:
The stent is coated with Everolimus, a proven anti-proliferative drug that helps prevent neointimal hyperplasia, thereby significantly reducing the risk of in-stent restenosis and target lesion revascularization.

Key Features:

• Material: Cobalt Chromium alloy – provides excellent strength-to-thickness ratio with enhanced radiopacity.

• Drug: Everolimus – controlled and uniform drug release for effective suppression of restenosis.

• Strut Thickness: Ultra-thin design for better vessel conformability and faster endothelialization.

• Polymer Coating: Biocompatible polymer ensures controlled drug release and minimizes inflammatory response.

• Flexibility & Deliverability: Excellent trackability through tortuous anatomy and easy deployment in challenging lesions.

• Clinical Benefit: Lower incidence of stent thrombosis, restenosis, and improved long-term clinical outcomes.

Indications:

• Treatment of patients with coronary artery disease (CAD) requiring percutaneous coronary intervention (PCI).

• Suitable for de novo lesions in native coronary arteries, including small vessels and complex anatomies.

Benefits for Patients & Physicians:

• Minimizes the risk of restenosis.

• Promotes rapid healing and endothelial coverage.

• Provides durable clinical outcomes with a proven safety profile.

• Enables precise placement with high procedural success.